Humulin 70/30 Vial 100 Units / ml
Humulin 70/30 (human insulin isophane suspension and human insulin injection) is a mixture of 70% human insulin isophane, intermediate-acting human insulin, and 30% human insulin, short-acting human insulin. Human insulin is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli. Humulin 70/30 is a suspension of crystals made from combining human insulin and protamine sulfate under appropriate conditions for crystal formation and mixing with human insulin injection.
This medication is a white and cloudy suspension that contains human insulin isophane suspension (NPH) and human insulin injection (regular) for subcutaneous use. Each milliliter contains 100 units of human insulin, 0.24 mg of protamine sulfate, 16 mg of glycerin, 3.78 mg of dibasic sodium phosphate, 1.6 mg of metacresol, 0.65 mg of phenol, zinc oxide content adjusted to provide 0.025 mg zinc ion, and Water for Injection.
This medication is injected under the skin. It should not be injected into a vein or muscle. Doses of insulin are measured in units. U-100 insulins, including Humulin 70/30, contain 100 units/mL. Humulin 70/30 should be given subcutaneously approximately 30-45 minutes before a meal. Humulin 70/30 also comes in cartridges,
Warnings & Precautions
Humalog insulin should not be injected into a muscle or vein.
Do not use Humulin 70/30 insulin if you are experiencing low blood sugar (hypoglycemia).
Do not share syringes and needles with others as this can lead to spreading infection.
Do not use Humulin 70/30 if you have allergic reactions to insulin or experiencing a hypoglycemic episode.
This medication should not be used by anyone younger than the age of 18.
Notify your doctor if you have any liver, heart, or kidney disease or low potassium levels. Let them know if you are currently taking rosiglitazone or pioglitazone or are breastfeeding or pregnant.
Be sure to follow instructions by your doctor or pharmacist, especially if you are pregnant or breastfeeding. Managing diabetics is essential during pregnancy since high blood sugars can cause complications for both mother and baby.
After mixing, Humulin 70/30 should look cloudy. Do not use it if it appears precise or has particles or white material at the bottom. If medication seems compromised, contact your pharmacist to arrange a new one.
Read instructions that come with medication, follow instructions provided by your doctor, nurse, or pharmacist.
Do not withdraw insulin from the Humulin pen using a syringe.
Do not operate heavy machinery or drive until you understand how your body responds to the medication.
Do not drink alcohol after using. See effects of alcohol on diabetes.
Keep the medication out of reach from children and pets.
Before Taking Humulin 70/30
Before using Humulin 70/30, tell your healthcare provider about all your medical conditions, including, if you:
– have liver or kidney problems.
– take any other medicines, especially ones commonly called TZDs (thiazolidinediones).
– have heart failure or other heart problems. If you have heart failure, it may get worse while you take TZDs with Humulin 70/30.
– are pregnant, planning to become pregnant. Talk with your healthcare provider about the best way to control your blood sugar if you plan to become pregnant or while you are pregnant.
– are breastfeeding or plan to breastfeed. Humulin 70/30 may pass into your breast milk. Talk with your healthcare provider about the best way to feed your baby while using Humulin 70/30.
– are taking new prescription or over-the-counter medicines, vitamins, or herbal supplements.
Tell your doctor if you are currently taking any over-the-counter medications, herbal supplements, vitamins, or other prescription medication.
Humulin 70/30 should be used as instructed by your doctor, pharmacist, or nurse. Review instructions that come with medication and prescription labels.
Do not increase or decrease dosages or for longer than as directed by your physician.
Humulin 70/30 insulin should be injected under the skin. Your doctor or nurse should show you how to inject correctly and how to dispose of syringes and needles.
Do not inject into a muscle or vein.
Humulin 70/30 should not be mixed with other insulin or used with an insulin pump.
Your doctor should instruct on where to inject insulin. Rotate injection sites to avoid causing skin complications. Do not inject into skin that is tender, pitted, bruised, thickened, scaly, damaged, or has lumps.
Eat a meal within 30-45 minutes after injection.
If you use an injection pen, only use the one that comes with the Humulin 70/30.
Follow local and state laws for proper disposal of needles and syringes. Use a “sharps” disposal container that is puncture-proof. Speak to your pharmacist about how and where to properly dispose of medication and used medical supplies.
Your doctor may prescribe a glucagon kit in the event of high blood sugar (hyperglycemia). Be sure your friends and family understand how to apply the injection n case of emergency. Signs of hyperglycemia may include increased thirst and urination.
Surgery, illness, stress, alcohol use, exercise, or skipping meals can affect blood sugar levels. Speak to your doctor before you decide to change your insulin schedule.
Keep Humulin 70/30 insulin in its original container and away from light and heat.
Do not draw insulin into a syringe unless it is time for injection.
Do not freeze insulin or store near a cooling element.
Dispose of insulin that has previously been frozen.
The most common side effect experienced with insulin is low blood sugar (hypoglycemia).
Symptoms of hypoglycemia include hunger, sweating, pale skin, irritability, headache, shakiness, dizziness, poor concentration.
Severe cases of hypoglycemia can lead to insulin ketoacidosis, disorientation, unconsciousness, seizures, and death.
To avoid the effects of hypoglycemia, you should carry a glucose table, non-dietetic candy, or sugary drink—Monitor blood sugar levels.
Heart failure can result if insulin is taken with thiazolidinediones (TZD’s)
Notify your doctor if your symptoms get worse or you are experiencing symptoms such as shortness of breath, weight gain, or swelling of the ankles or feet.
The risk of hypoglycemia associated with Humulin 70/30 use may be increased when co-administered with antidiabetic agents, salicylates, sulfonamide antibiotics, monoamine oxidase inhibitors, fluoxetine, disopyramide, fibrates, pentoxifylline, ACE inhibitors, angiotensin II receptor blocking agents, and somatostatin analogs (e.g., octreotide).
Dose adjustment and increased frequency of glucose monitoring may be required when Humulin 70/30 is co-administered with these drugs.
It is essential to discuss with your healthcare provider any medications that you are currently using. If you add or subtract any medications, please let your healthcare provider know immediately.
Excess insulin administration may cause hypoglycemia and hypokalemia. Mild episodes of hypoglycemia can be treated with oral glucose. Adjustments in drug dosage, meal patterns, or physical activity levels may be needed. More severe episodes with coma, seizure or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because hypoglycemia may recur after apparent clinical recovery. Hypokalemia must be corrected appropriately.
Available data from published studies over decades have not established an association with human insulin use during pregnancy and significant congenital disabilities, miscarriage, or adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy. Animal reproduction studies were not performed.
The estimated background risk of significant congenital disabilities is 6-10% in women with pre-gestational diabetes with an HbA1c >7% and has been reported to be as high as 20-25% in women with an HbA1c >10%. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of significant congenital disabilities and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Dispense in the original sealed carton with the enclosed Instructions for Use. Protect from heat and light. Do not freeze. Please do not use it after the expiration date.
Not In-Use Humulin 70/30 Vials
Suppose refrigerated keep at 36° to 46°F (2° to 8°C), but not in the freezer. Do not use it if it has been frozen.
If in-room temperature, store below 86°F (30°C) the vial must be discarded after 31 days.
In-Use Humulin 70/30 Vials
If in the refrigerator, keep at36° to 46°F (2° to 8°C), but not in the freezer. Do not use it if it has been frozen. Vials must be used within 31 days or be discarded, even if they still contain Humulin 70/30.
If kept at room temperature, ensure they are not below 86°F (30°C). The vial must be discarded after 31 days, even if the vial still contains Humulin 70/30.